Base editing tool and application thereof
By designing a fusion protein containing TadA8e and SpCas9 (D10A) fragments, combined with nuclear localization signals, the problem of inefficiency of CGBE editing tools is solved, more efficient C-to-G base editing is achieved, and the editing window is expanded. Improves the application capabilities of editing tools.
Patent Information
- Application Number
- CN202410687404.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-30
- Publication Date
- 2024-11-15
AI Technical Summary
The existing CGBE editing tools have low targeted editing efficiency and narrow editing windows, which limit their application.
A fusion protein is developed that includes TadA8e (N46L, R26G, E27A, V28G) fragments and SpCas9 (D10A) fragments from the 5' to the 3' ends, and preferably includes a nuclear localization signal to form a more efficient CGBE editing tool.
It significantly improves the efficiency of C-to-G base editing, and improves the editing efficiency of existing tools by 1.4 times to 13.4 times on average, expands the editing window, and enhances the application potential of editing tools.
Smart Images

Figure HDA0004867439930000011 
Figure HDA0004867439930000021 
Figure HDA0004867439930000031
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of gene editing, and specifically relates to a fusion protein of a base editor and applications thereof. Background Art
[0002] The results of mutation site analysis in the ClinVar database show that 58% of human pathogenic mutations are point mutations. Therefore, effective single-base editing is crucial for the simulation and repair of human pathogenic mutations. The CRISPR / Cas system is currently the most widely used gene editing system, but the editing of target sites by this system depends on the generation of double-strand breaks in the genome, and the efficiency of single-base editing in this system is also low. In order to overcome the above limitations, one method is to fuse the Cas9 nickase with different base modification enzymes to further develop cytosine base editors (CBE) and adenine base editors (ABE) with higher single-base editing efficiency, which can achieve C-to-T and A-to-G base editing, respectively. Compared with the Cas9 editing system, base editors only cause single-strand breaks in DNA and have higher genomic safety. In addition, the sgRNA design of base editors is simple, making it easier to achieve efficient targeted base editing. Currently, base editors have been widely used in a large number of preclinical studies. For example, Verve-101 developed by Verve Therapeutics uses ABE8.8m to edit the splicing site of the PCSK9 gene in vivo, permanently shutting down the expression of PCSK9 protein in the liver, and is expected to achieve a one-time cure for hypercholesterolemia. However, base editors cannot achieve base mutations other than C-to-T and A-to-G. In order to further expand the single-base mutation types of base editors, researchers have developed a CGBE editing tool that can cause C-to-G base editing based on CBE and ABE.
[0003] The CGBE editing tool uses DNA glycosylase to remove the uracil base from the genome after cytosine deamination to form a purine / pyrimidine site. Eukaryotic cells tend to introduce cytosine bases in the opposite strand of the apurine / pyrimidine site, thereby introducing a C-to-G base mutation at the target site. However, the existing CGBE editing tools have low targeted editing efficiency and a narrow editing window, which severely limits the application of CGBE editing tools. Therefore, it is necessary to develop a CGBE editing tool with higher editing efficiency. Summary of the invention
[0004] The problem to be solved by the present invention is to overcome the problem of low CGBE editing efficiency in the prior art, thereby providing a CGBE fusion protein with higher editing efficiency and its application.
[0005] According to a first aspect of the present invention, a fusion protein is provided, which comprises, from the 5' end to the 3' end, a TadA8e (N46L, R26G, E27A, V28G) fragment and a SpCas9 (D10A) fragment; the amino acid sequence of the TadA8e (N46L, R26G, E27A, V28G) fragment is shown in SEQ ID NO: 1.
[0006] The SpCas9 (D10A) fragment is SpCas9 (D10A) with PAM being NGG or SpCas9 (D10A) with PAM being NG, the amino acid sequence of the former being shown in SEQ ID NO:3, and the amino acid sequence of the latter being shown in SEQ ID NO:5.
[0007] The fusion protein also preferably includes a nuclear localization signal.
[0008] Preferably, the nuclear localization signal is located at the 5' end and / or 3' end of the fusion protein, and the amino acid sequence is shown in SEQ ID NO:7.
[0009] The amino acid sequence of the fusion protein is preferably as shown in SEQ ID NO:9 or SEQ ID NO:11.
[0010] According to a second aspect of the present invention, a nucleic acid construct is provided, which comprises a polynucleotide encoding the above fusion protein.
[0011] Preferably, the nucleotide sequence encoding the TadA8e (N46L, R26G, E27A, V28G) fragment is as shown in SEQ ID NO: 2.
[0012] The nucleotide sequence encoding the SpCas9(D10A) fragment with PAM being NGG is shown in SEQ ID NO:4.
[0013] The nucleotide sequence encoding the SpCas9 (D10A) fragment with PAM being NG is shown in SEQ ID NO:6.
[0014] The nucleotide sequence encoding the nuclear localization signal fragment is shown in SEQ ID NO:8.
[0015] More preferably, the nucleotide sequence encoding the fusion protein is shown as SEQ ID NO:10 or SEQ ID NO:12.
[0016] According to the third aspect of the present invention, a recombinant expression vector is provided, wherein the recombinant expression vector contains the above-mentioned nucleic acid construct.
[0017] Preferably, the backbone of the recombinant expression vector is pCMV.
[0018] According to a fourth aspect of the present invention, an expression system is provided, the expression system comprising the above-mentioned recombinant expression vector or the above-mentioned nucleic acid construct integrated into its genome;
[0019] Preferably, the starting host of the expression system is selected from eukaryotic cells or prokaryotic cells.
[0020] More preferably, the starting host is selected from mouse cells and human cells.
[0021] The starting host is more preferably 293T cells.
[0022] According to a fifth aspect of the present invention, there is provided a use of the above fusion protein, the above nucleic acid construct, the above recombinant expression vector or the above expression system in the preparation of a drug for a gene editing agent. Preferably, the drug is a drug for treating a genetic disease.
[0023] Compared with the prior art, the present invention can efficiently induce C-to-G base editing. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a schematic diagram of the base editor involved in the present invention.
[0025] Figure 2 is the editing efficiency of base editors at 24 endogenous sites.
[0026] Figure 3 Statistical results of base editor multi-site editing efficiency and multi-site editing byproducts.
[0027] Figure 4 This is the editing window of the base editor.
[0028] Figure 5 is the editing efficiency of the base editor at the three NG PAM sites.
[0029] Figure 6 Statistical results of editing efficiency and editing byproducts of the three NG PAM sites of the base editor.
[0030] Figure 7 Efficiency of base editors in introducing Alzheimer's disease-causing mutations.
[0031] Figure 8 Efficiency of base editors in introducing Alstrom syndrome pathogenic mutations.
[0032] Fig. 9 Efficiency of base editors in repairing pathogenic mutations in glycogen storage diseases.
[0033] Fig.10Efficiency of base editors in repairing severe combined immunodeficiency disease pathogenic mutations.
[0034] Fig.11 Efficiency of base editors in repairing pathogenic mutations in hereditary non-syndromic deafness.
[0035] Fig.12 The efficiency of base editors in editing PCSK9 in Huh7 cells.
[0036] Fig.13 The results of base editor knocking down PCSK9 protein expression in Huh7 cells. DETAILED DESCRIPTION
[0037] The present invention is further described (but not limited) by the following drawings and specific embodiments.
[0038] Example 1
[0039] First, based on ABE8e (Addgene #138489), primers were designed with reference to the instructions of ClonExpress MultiS One Step Cloning Kit (Vazyme, C113-01) to construct Td-CGBE, 8e-46+3-nCas9, eUNG-Td-CGBE and eUNG-8e-46+3-nCas9, as well as Td-CGBE-NG, 8e-46+3-nCas9-NG and eUNG-8e-46+3-nCas9-NG; based on AncBE4max (Addgene #112094), primers were designed with reference to the instructions of the aforementioned kit to construct the CGBE1 vector. The schematic diagram of each base editor is shown below: Figure 1 shown.
[0040] The amino acid sequence of ABE8e is shown in SEQ ID NO:13.
[0041] The amino acid sequence of Td-CGBE is shown in SEQ ID NO:14.
[0042] The amino acid sequence of 8e-46+3-nCas9 is shown in SEQ ID NO:9.
[0043] The amino acid sequence of eUNG-Td-CGBE is shown in SEQ ID NO:15.
[0044] The amino acid sequence of eUNG-8e-46+3-nCas9 is shown in SEQ ID NO:16.
[0045] The amino acid sequence of Td-CGBE-NG is shown in SEQ ID NO:18.
[0046] The amino acid sequence of 8e-46+3-nCas9-NG is shown in SEQ ID NO:11.
[0047] The amino acid sequence of CGBE1 is shown in SEQ ID NO:17.
[0048] The amino acid sequence of eUNG-8e-46+3-nCas9-NG is shown in SEQ ID NO:19.
[0049] Example 2
[0050] In this example, the constructed base editors ABE8e, Td-CGBE, 8e-46+3-nCas9, eUNG-Td-CGBE, eUNG-8e-46+3-nCas9 and CGBE1 were tested for editing efficiency at 24 endogenous gene sites in 293T cells.
[0051] 2.1 Construction of sgRNA plasmid
[0052] The sgRNA sequence targeting the 293T cell genome is shown in SEQ ID NO: 20-43. ACCG is added to the 5' end of the sgRNA sequence as the upstream sequence, and AAAC is added to the 5' end of the sgRNA reverse complementary sequence as the downstream sequence. After oligo synthesis, the upstream and downstream sequences are annealed (the program is: 95℃, 5min; 95℃-85℃at-2℃ / s; 85℃-25℃at-0.1℃ / s; hold at 16℃) and then connected to the pGL3-U6-sgRNA (Addgene#51133) vector after BsaI (NEB: R3733L) digestion. The digestion system is: pGL3-U6-sgRNA 2μg; CutSmart buffer (NEB: B7204S) 6μL; BsaI 1μL; ddH2O is made up to 60μL, and digestion is carried out at 37℃ overnight. The ligation system is: Solution I (Takara: 6022Q) 3μL; digested vector 1μL; annealed product 6μL, ligated at 16℃ for 30min, then transformed, picked, and identified. Positive clones were shaken to extract plasmids (Axygene: AP-MN-P-250G), and the concentration was measured for later use.
[0053] 2.2 Cell culture and transfection
[0054] HEK293T cells were inoculated and cultured in DMEM medium (Gibco: C11995500BT) supplemented with 10% serum (Gibco: 10270-106), which contained 1% double antibody (v / v) (Gibco: 15140122). 24-well plates were plated one day before transfection so that the cell density during transfection reached about 80%. The amount of plasmids transfected in each well was 750 ng of base editor plasmid and 250 ng of sgRNA plasmid (the sequence of sgRNA1-24 is shown in SEQ ID NO: 20 to SEQ ID NO: 43), respectively. The plasmids were diluted in 25 μL of opti-MEM; 3 μL of transfection reagent LipoMax (SUDGEN) was diluted in 25 μL of opti-MEM; finally, the diluted transfection was placed at room temperature for 5 minutes and then added to the diluted plasmid, mixed and placed at room temperature for 20 minutes. The incubated plasmid-transfection reagent mixture was added to a 24-well plate, and fresh culture medium was added 6 hours after transfection. Transfection-positive cells were flow-sorted 3 days after transfection.
[0055] 2.3 Detection of editing efficiency
[0056] After centrifuging the sorted cells and removing the supernatant, add lysis buffer (50mM KCl, 1.5mM MgCl2, 10mMTris pH 8.0, 0.5% Nonidet P-40, 0.5% Tween 20, 100μg / ml protease K), and use the cell lysis buffer as a template to amplify the target sequence. The amplification system is: 2×buffer (Vazyme: P505) 25μL; dNTP 1μL; Forward Primer (10μmol / L) 1μL; Reverse Primer (10pmol / L) 1μL; cell lysis product 1μL; DNA polymerase (Vazyme: P505) 0.5μL; ddH2O is added to make up to 50μL.
[0057] The amplified PCR products were purified according to the instructions of the PCR product recovery kit (Axygen: AP-PCR-250G). The purified PCR products were sent for Sanger sequencing or deep sequencing to analyze the editing efficiency of the base editor at the target site (SEQ ID NO: 20-43).
[0058] Related results such as Figure 2-4 shown. Figure 2The results showed that among the 24 endogenous targets, the C-to-G editing efficiency of 8e-46+3-nCas9 and eUNG-8e-46+3-nCas9 at 11 targets was significantly higher than that of Td-CGBE (an average increase of 1.6 to 13.4 times), and the editing efficiency at other sites was mostly equivalent to or slightly higher than that of Td-CGBE, and was lower than that of Td-CGBE only in SG1-C5, SG5-C5, and SG9-C7; the editing efficiency of 8e-46+3-nCas9 and eUNG-8e-46+3-nCas9 was equivalent at most targets; at other sites except SG4-C7 and SG24-C6, the editing activity of the new CGBE 8e-46+3-nCas9 and eUNG-8e-46+3-nCas9 was higher than or equivalent to that of CGBE1.
[0059] Figure 3 The statistical results of multi-point editing efficiency in (A) show that the average C-to-G editing efficiencies of Td-CGBE, eUNG-Td-CGBE, 8e-46+3-nCas9, eUNG-8e-46+3-nCas9, and CGBE1 are 11.75%, 11.13%, 15.83%, 14.66%, and 10.23%, respectively. The editing efficiency of 8e-46+3-nCas9 is 1.4 times and 1.6 times higher than that of the existing editing tools Td-CGBE and CGBE1, respectively. Figure 3 The statistical results of multi-point editing byproducts in (B) show that the frequency of editing byproducts of eUNG-Td-CGBE and eUNG-8e-46+3-nCas9 is slightly lower than that of Td-CGBE and 8e-46+3-nCas9.
[0060] Figure 4 The results of the editing window showed that the main editing active site of CGBE1 was C6, and the editing efficiency at other positions was low; the editing activity of ABE-derived CGBEs at C4 and C5 was significantly higher than that of CGBE1. 8e-46+3-nCas9 significantly improved the C-to-G editing efficiency at C4-C6. Compared with Td-CGBE, the editing efficiency of 8e-46+3-nCas9 in the C4-C6 window was increased by 2.6 times, 1.3 times, and 1.2 times, respectively. Compared with CGBE1, the editing efficiency of 8e-46+3-nCas9 in the C4-C6 window was increased by 3 times, 2.9 times, and 1.2 times, respectively.
[0061] Example 3
[0062] In this example, the constructed base editors Td-CGBE, Td-CGBE-NG, 8e-46+3-nCas9-NG and eUNG-8e-46+3-nCas9-NG were tested for editing efficiency at three endogenous gene sites (PAM sequence was NG) in 293T cells.
[0063] The construction of sgRNA is carried out according to 2.1 of Example 2, and the sequence of sgRNA is shown in SEQ ID NO: 44-46. Cell culture and transfection are carried out according to 2.2 of Example 2. The detection of editing efficiency is carried out according to 2.3 of Example 2.
[0064] Related results such as Figure 5-6 shown. Figure 5 The results showed that among the three endogenous targets, the C-to-G editing efficiency of eUNG-8e-46+3-Cas9-NG was slightly lower than or equivalent to that of 8e-46+3-Cas9-NG; the C-to-G editing efficiency of 8e-46+3-Cas9-NG at NG2-C5 and NG3-C7 reached 45% and 20%, respectively, which were significantly higher than those of Td-CGBE-NG; for NG1-C5, its C-to-G editing efficiency was slightly higher than that of Td-CGBE-NG.
[0065] Figure 6 The statistical results of multi-point editing efficiency in (A) show that the average C-to-G editing efficiencies of Td-CGBE-NG, 8e-46+3-Cas9-NG, and eUNG-8e-46+3-Cas9-NG are 9.96%, 17.68%, and 16.17%, respectively; the editing efficiency of 8e-46+3-Cas9-NG is 1.78 times that of Td-CGBE-NG. Figure 6 The statistical results of editing by-products in (B) show that 8e-46+3-nCas9-NG and eUNG-8e-46+3-nCas9-NG produce more editing by-products than Td-CGBE-NG, among which 8e-46+3-nCas9-NG produces more editing by-products than eUNG-8e-46+3-nCas9-NG.
[0066] Example 4
[0067] In this example, Td-CGBE and 8e-46+3-nCas9 were tested for their ability to mimic disease-causing mutations in 293T cells.
[0068] The construction of sgRNA is carried out according to 2.1 in Example 2, and the sequence of sgRNA is shown in SEQ ID NO: 47-48. The sgRNA with the sequence shown in SEQ ID NO: 47 is used to simulate the pathogenic point mutation PSEN1c.811C>G of Alzheimer's disease; the sgRNA with the sequence shown in SEQ ID NO: 48 is used to simulate the pathogenic point mutation ALMS1 c.4004C>G of Alstrom syndrome. Cell culture and transfection are carried out according to 2.2 in Example 2. The detection of editing efficiency is carried out according to 2.3 in Example 2.
[0069] Related results such as Figure 7-8 shown. Figure 7 The Sanger sequencing results showed that the efficiency of Td-CGBE and 8e-46+3-nCas9 in introducing the PSEN1 c.811C>G mutation into the 293T cell genome was 8% and 40%, respectively. The editing efficiency of 8e-46+3-nCas9 at this site was 4 times that of the existing editing tool Td-CGBE. Figure 8 The Sanger sequencing results showed that the efficiency of Td-CGBE and 8e-46+3-nCas9 in introducing the ALMS1 c.4004C>G mutation into the 293T cell genome was 27% and 46%, respectively. The editing efficiency of 8e-46+3-nCas9 at this site was 1.7 times that of the existing editing tool Td-CGBE.
[0070] Example 5
[0071] In this example, the ability of Td-CGBE and 8e-46+3-nCas9 to repair disease-causing mutations in a 293T disease cell model was tested.
[0072] The construction of sgRNA is carried out with reference to 2.1 in Example 2, and the sequence of sgRNA is shown in SEQ ID NO: 49-51. The sgRNA with the sequence shown in SEQ ID NO: 49 is used to repair the pathogenic point mutation GAA c.444C>G in glycogen storage disease; the sgRNA with the sequence shown in SEQ ID NO: 50 is used to repair the pathogenic point mutation RAG1c.1653C>G in severe combined immunodeficiency disease; the sgRNA with the sequence shown in SEQ ID NO: 51 is used to repair the pathogenic point mutation MYO7A c.3171C>G in hereditary non-syndromic deafness. Cell culture and transfection are carried out with reference to 2.2 in Example 2. The detection of editing efficiency is carried out with reference to 2.3 in Example 2.
[0073] Related results such as Figure 9-11 shown. Fig. 9The Sanger sequencing results showed that the repair efficiencies of Td-CGBE-NG and 8e-46+3-nCas9NG for GAA c.444C>G were 17% and 39%, respectively. The repair efficiency of 8e-46+3-nCas9NG at this site was 2.3 times that of the existing editing tool Td-CGBE. Fig.10 The Sanger sequencing results showed that the repair efficiencies of Td-CGBE and 8e-46+3-nCas9 for RAG1 c.1653C>G were 21% and 46%, respectively. The repair efficiency of 8e-46+3-nCas9 at this site was 2.2 times that of the existing editing tool Td-CGBE. Fig.11 The Sanger sequencing results showed that the repair efficiencies of Td-CGBE and 8e-46+3-nCas9 for MYO7Ac.3171C>G were 8% and 49%, respectively. The repair efficiency of 8e-46+3-nCas9 at this site was 6.1 times that of the existing editing tool Td-CGBE.
[0074] Example 6
[0075] In this example, the ability of Td-CGBE and 8e-46+3-nCas9 to knock down PCSK9 gene expression in Huh7 cells was tested.
[0076] 6.1 Construction of sgRNA
[0077] The construction of sgRNA was carried out with reference to 2.1 in Example 2, and the sequence of sgRNA is shown in SEQ ID NO: 52-53. The sgRNA with the sequence shown in SEQ ID NO: 52 is the sgRNA for editing the PCSK9 gene by Td-CGBE-NG and 8e-46+3-nCas9 NG; the sgRNA with the sequence shown in SEQ ID NO: 53 is the sgRNA for editing the PCSK9 gene by AncBE4max (Addgene#112094). Td-CGBE-NG and 8e-46+3-nCas9 NG introduce premature stop codons by generating C-to-G mutations, and AncBE4max introduces premature stop codons by generating C-to-T mutations. Therefore, Td-CGBE-NG and 8e-46+3-nCas9NG can theoretically achieve the same decrease in PCSK9 protein expression as AncBE4max.
[0078] 6.2 Cell culture and transfection
[0079] Huh7 cells were inoculated and cultured in DMEM medium (Gibco: C11995500BT) supplemented with 10% serum (Gibco: 10270-106), containing 1% bispecific antibody (v / v) (Gibco: 15140122). A 24-well plate was plated one day before transfection so that the cell density during transfection reached about 80%. The amount of plasmids transfected in each well was 750 ng of base editor plasmid and 250 ng of sgRNA plasmid (sequences as shown in SEQ ID NO: 52 and SEQ ID NO: 53). The plasmids were diluted in 50 μL of opti-MEM, and 3 μL of transfection reagent was added. 2020 (MIR 5400), mix well and place at room temperature for 30 minutes. Add the incubated plasmid-transfection reagent mixture to a 24-well plate, replace with fresh culture medium 6 hours after transfection, and flow sort transfection-positive cells 3 days after transfection.
[0080] 6.3 Detection of editing efficiency
[0081] Refer to 2.3 in Example 2.
[0082] 6.4Western Blot
[0083] After centrifugation of the sorted transfected positive cells, the supernatant was discarded, RIPA lysis buffer was added, and the supernatant was aspirated after centrifugation at 4°C and 12 000g for 15 minutes. Part of the supernatant was taken for protein quantification. 20 μg of total protein was taken from the Huh7 unedited group, Td-CGBE-NG edited group, 8e-46+3-nCas9 NG edited group, and AncBE4max edited group for SDS-PAGE electrophoresis. The protein in the PAGE gel was then transferred to a PVDF membrane by wet transfer, blocked with 5% skim milk for 1 hour, incubated with the primary antibody at 4°C overnight, washed the membrane 6 times the next day, incubated with the secondary antibody at room temperature for 1 hour, and then washed the membrane 3 times before development.
[0084] Related results such as Figure 12-13 shown. Fig.12 The Sanger sequencing results showed that Td-CGBE-NG and 8e-46+3-nCas9 NG underwent C-to-G editing at the target site shown in SEQ ID NO: 52, with efficiencies of 33% and 34%, respectively; AncBE4max underwent C-to-T editing at the target site shown in SEQ ID NO: 53, with an efficiency of 25%. Fig.13Western Blot results showed that compared with the Huh7 unedited group, the expression of PCSK9 protein in the Td-CGBE-NG edited group, 8e-46+3-nCas9 NG edited group, and AncBE4max edited group was significantly reduced. Therefore, CGBE, like CBE, can knock out targeted genes by introducing premature stop codons.
[0085] In summary, the fusion proteins 8e-46+3-nCas9 and 8e-46+3-nCas9 NG provided by the present invention can more efficiently cause C-to-G base editing, and provide a more efficient editing tool for the research and treatment of C-to-G or G-to-C pathogenic mutations and gene knockout. In addition, the present invention can not only more efficiently simulate and repair pathogenic point mutations, but also knock out target genes by introducing stop codons in advance.
Claims
1. A fusion protein of a base editor, which comprises a TadA8e (N46L, R26G, E27A, V28G) fragment and a SpCas9 (D10A) fragment from the 5' end to the 3' end, in: The amino acid sequence of the TadA8e (N46L, R26G, E27A, V28G) fragment is shown in SEQ ID NO: 1; The SpCas9 (D10A) fragment is: SpCas9 (D10A) with PAM being NGG or SpCas9 (D10A) with PAM being NG, the amino acid sequence of the former being shown in SEQ ID NO:3, and the amino acid sequence of the latter being shown in SEQ ID NO:
5. 2 . The fusion protein according to claim 1 , further comprising a nuclear localization signal, wherein the nuclear localization signal fragment is located at the 5′ end and / or the 3′ end of the fusion protein.
3. The fusion protein according to claim 2, wherein the amino acid sequence of the nuclear localization signal is shown in SEQ ID NO:
7. 4 . The fusion protein according to claim 1 , wherein the amino acid sequence of the fusion protein is as shown in SEQ ID NO: 9 or as shown in SEQ ID NO:
11.
5. A nucleic acid construct comprising a polynucleotide encoding the fusion protein according to any one of claims 1 to 4.
6. The nucleic acid construct according to claim 5, in: The nucleotide sequence encoding the TadA8e (N46L, R26G, E27A, V28G) fragment is shown in SEQ ID NO: 2; The nucleotide sequence of SpCas9(D10A) encoding the SpCas9(D10A) fragment whose PAM is NGG is shown in SEQ ID NO:4; The nucleotide sequence encoding the nuclear localization signal fragment is shown in SEQ ID NO: 8; The polynucleotide sequence encoding the fusion protein is shown in SEQ ID NO:
10.
7. The nucleic acid construct according to claim 5, in: The nucleotide sequence encoding the TadA8e (N46L, R26G, E27A, V28G) fragment is shown in SEQ ID NO: 2; The nucleotide sequence of SpCas9(D10A) encoding the SpCas9(D10A) fragment with PAM of NG is shown in SEQ ID NO:6; The nucleotide sequence encoding the nuclear localization signal fragment is shown in SEQ ID NO: 8; The polynucleotide sequence encoding the fusion protein is shown in SEQ ID NO:
12.
8. A recombinant expression vector comprising the nucleic acid construct according to any one of claims 5 to 7, wherein the backbone of the recombinant expression vector is pCMV.
9. An expression system comprising the recombinant expression vector according to claim 8 or a nucleic acid construct according to any one of claims 5 to 7 integrated into its genome, wherein the starting host of the expression system is selected from eukaryotic cells or prokaryotic cells.
10. Use of the fusion protein according to any one of claims 1 to 4, the nucleic acid construct according to any one of claims 5 to 7, the recombinant expression vector according to claim 8, or the expression system according to claim 9 in the preparation of a gene editing agent.
